The IDIBELL colorectal cancer research team, led by Dr. Vïctor Moreno, has contributed to a large-scale study that led to the description of 11 new genetic variants associated with this type of cancer. This study, published in in the Journal of the National Cancer Institute, provides insight into the architecture of common genetic variation contributing […]
Novel Common Genetic Susceptibility Loci for Colorectal Cancer Read More »
The best-known way our cells and tissues store biological information is their genetic code, derived from the DNA sequence (Deoxyribonucleic Acid). During the last two decades, the epigenetic code has been identified as capable of controlling our DNA through a series of chemical tags. Today, an article published in Cell by Manel Esteller, coordinator of
The Third Warehouse of Biological Information: The RNA Code Read More »
Hereditary Colorectal Cancer. Genetic Basis and Clinical Implications Researchers of the Hereditary Cancer Program of the Catalan Institute of Oncology, IDIBELL (Oncobell), Dr. Laura Valle and Dr. Gabriel Capellá, together with Dr. Stephen B. Gruber of the Norris Comprehensive Cancer Center (University of Southern California), have published a book on hereditary colorectal cancer entitled “Hereditary
New books by IDIBELL authors: hereditary colorectal cancer & stem cell genetics Read More »
Under the coordination of the University of Turin in Italy, members of the EurOPDX Consortium and additional key European academic and SME partners recently secured 5 million € from the European Union’s Horizon 2020 research and innovation programme to build an infrastructure for access to patient-derived cancer xenograft (PDX) models and related data, for academic
On June 21st, the training session “How to support researchers in writing competitive proposals for Horizon 2020” was held at the Duran i Reynals hospital. The course, part of the ICABELL project, was taught by Dr. Sean McCarthy, expert in European funding for research projects. The session, which had a high degree of attendance,
Specialised training session for H2020 project managers Read More »
A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival
New combined treatment shows promise in Hepatocellular Carcinoma Read More »
Cisplatin is one of the chemotherapeutic agents more frequently used by oncologists to treat tumors. Cisplatin-based chemotherapy is very efficient but frequently cancer cells adjust its molecular mechanisms to become resistant to cisplatin. The IDIBELL research group “Modeling Human diseases in C. elegans”, led by Julián Cerón, have been using a microscopic worm to investigate
Ernest Nadal and Samuel Gonçalves are awarded research grants to advance in cancer research
Two new AECC grants for IDIBELL researchers Read More »
In recent years, immunotherapy has been consolidated as one of the new and principal hopes in the fight against cancer. This therapeutic approach is based on the fact that our immune system is constantly watching the presence of strange presences within the body and fighting them. When a tumor originates, its mutations make cancer cells
New discoveries towards the improvement of the immunotherapy treatment of lung cancer Read More »
The clinical application of an inhibitor of the SHP2 protein (also called PTPN11) could be effective, in the near future, in patients affected by one of the main types of lung cancer, the so-called Non-small cell lung cancer (NSCLC). This is the conclusion reached by an international research team including doctors Alberto Villanueva and Ernest
New drug against of the main types of lung cancer Read More »
